Wall Street analysts generally evaluate ADC Therapeutics as a speculative high-risk, high-reward growth opportunity rather than an outright sell. Proponents point to the commercial progress of its lead product Zynlonta and a maturing oncology pipeline, while cautious analysts emphasize ongoing financial losses, cash burn rates, and clinical trial risks, recommending that investors carefully align any position with their individual risk tolerance.